Bayer (1BAYN) AI Stock Analysis

10 Followers

Bayer

(Milan:1BAYN)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Pharmaceutical pipeline momentumThe China approval gives Bayer a meaningful pipeline asset and expands its pharmaceutical growth options beyond existing products. Asundexian’s first-in-class status may support further regulatory filings, future commercialization, and a broader platform for rebuilding durable Pharma growth.

Negative Factors

Recurring net lossesRepeated net losses indicate that Bayer’s substantial revenue base is not consistently converting into shareholder earnings. Persistent bottom-line weakness can constrain reinvestment, reduce financial flexibility, and make future performance more dependent on successful cost, portfolio, and pipeline execution.

Bayer (1BAYN) vs. iShares MSCI Italy ETF (EWI)

Market Cap: EUR 53.29B
Dividend Yield: 0.20%
Average Volume (3M): 17.52K
Price to Earnings (P/E): -38.2
Beta (1Y): 0.72
Revenue Growth: -1.73%
EPS Growth: 49.15%
Country: Italy
Employees: 87,830
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - General

Bayer Business Overview & Revenue Model

Company Description

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer...

Bayer Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IT:1BAYN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:BEI	77Outperform	EUR 18.32B	19.96	10.66%	1.16%	-2.50%	8.61%
DE:AFX	73Outperform	EUR 3.20B	21.44	5.52%	1.54%	-0.06%	-38.81%
DE:BAS	69Neutral	EUR 48.46B	8.43	16.48%	4.01%	-3.87%	2071.79%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
DE:COP	53Neutral	EUR 1.48B	43.42	4.19%	1.76%	―	―

* General Sector Average

Performance Comparison

IT:1BAYN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IT:1BAYN	Bayer Ag (UK)	55.44	29.01	109.79%
DE:BAS	BASF SE (UK)	54.28	13.03	31.58%
DE:BEI	Beiersdorf AG	85.26	-6.21	-6.79%
DE:AFX	Carl Zeiss Meditec	34.96	-6.35	-15.37%
DE:COP	CompuGroup Medical	28.30	4.45	18.66%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Bayer AI Stock Analysis